Dr. Christine Green · Viata Medical

Medications Safety Information

This notice describes how medical information about you may be used and disclosed. Please review it carefully.

Compound Semaglutide Safety Information

Your medical provider may recommend compounded semaglutide based on a medical review. Compounded drugs are not FDA approved and are not evaluated for safety, effectiveness, or quality standards. This document is a summary of product information and does NOT have all possible information and potential side effects of the product. This is not medical advice and does not substitute advice from your health care provider.

Indications and Use

Compounded semaglutide is an injectable prescription medicine that may help adults and adolescents with obesity and excess weight lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Compounded semaglutide should not be used with other semaglutide-containing products or any other GLP-1/GIP receptor agonist medicines.

Warning: Risk of Thyroid C-Cell Tumors

In studies with mice and rats, semaglutide caused thyroid tumors, including thyroid cancer. It is not known if compounded semaglutide will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. Do not use compounded semaglutide if you or any of your family have ever had MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Who Should Not Use Compounded Semaglutide

  • You or any of your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • You have a known allergic reaction to compounded semaglutide.

Common Side Effects

Nausea, vomiting, diarrhea, constipation, abdominal pain, upset stomach, abdominal distension, reflux, headache, fatigue, and dizziness. Swelling, redness, and itchiness at the injection site may occur. If any of these effects last or get worse, tell your provider or pharmacist promptly.

Serious Side Effects — Seek Immediate Medical Attention

  • Thyroid C-Cell Tumors: lump or swelling in neck, hoarseness, trouble swallowing, shortness of breath
  • Inflammation of Pancreas (Acute Pancreatitis): severe abdominal pain that does not go away
  • Acute Gallbladder Disease: pain in upper stomach, jaundice, fever, clay-colored stools
  • Low Blood Sugar (Hypoglycemia): dizziness, blurred vision, mood changes, sweating, fast heartbeat
  • Acute Kidney Injury: change in amount of urine, dehydration
  • Serious Allergic Reactions: swelling of face/lips/tongue/throat, severe rash, trouble breathing
  • Diabetic Retinopathy: changes in vision
  • Suicidal Behavior and Ideation: sudden changes in mood, behaviors, thoughts, or feelings

Legal Disclaimers — Semaglutide

Compounded semaglutide is not approved by the FDA. The FDA does not evaluate compounded products for safety, effectiveness, or quality. Ozempic®, Wegovy®, Saxenda®, and Victoza® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Viata Medical Group has no affiliation with Novo Nordisk or Eli Lilly.

Compound Tirzepatide Safety Information

Your medical provider may recommend compounded tirzepatide based on a medical review. Compounded drugs are not FDA approved and are not evaluated for safety, effectiveness, or quality standards.

Indications and Use

Compounded tirzepatide is an injectable prescription medicine that may help adults and adolescents with obesity and excess weight lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Compounded tirzepatide should not be used with other tirzepatide-containing products or any other GLP-1/GIP receptor agonist medicines.

Warning: Risk of Thyroid C-Cell Tumors

In studies with mice and rats, tirzepatide caused thyroid tumors, including thyroid cancer. It is not known if compounded tirzepatide will cause thyroid tumors or MTC in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. Do not use compounded tirzepatide if you or any of your family have ever had MTC or MEN 2.

Common Side Effects

Nausea, vomiting, diarrhea, constipation, abdominal pain, upset stomach, abdominal distension, reflux, headache, fatigue, and dizziness. Swelling, redness, and itchiness at the injection site may occur.

Legal Disclaimers — Tirzepatide

Compounded tirzepatide is not approved by the FDA. The FDA does not evaluate compounded products for safety, effectiveness, or quality. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Ozempic®, Wegovy®, Saxenda®, and Victoza® are registered trademarks of Novo Nordisk A/S. Viata Medical Group has no affiliation with Novo Nordisk or Eli Lilly.

Testosterone Safety Information

Indications / Use

  • Primary hypogonadism (congenital or acquired) in men
  • Hypogonadotropic hypogonadism (congenital or acquired) in men
  • Delayed puberty in adolescent males (selected cases, typically short-term)

Contraindications

  • Known or suspected prostate cancer or breast cancer in men
  • Pregnancy and breastfeeding
  • Hypersensitivity to testosterone or any component of the formulation
  • Serious cardiac, hepatic, or renal disease
  • Elevated hematocrit (>54%)
  • Untreated/uncontrolled sleep apnea

Common Side Effects

Acne, oily skin, increased hair growth, gynecomastia, mood changes, hot flashes/night sweats, hypertension, polycythemia (increased hematocrit), reduced sperm production, testicular atrophy, poor sleep, sleep apnea worsening, edema, nipple sensitivity.

How to Self-Administer Testosterone Injections

Always follow the guidance of your healthcare provider before starting or adjusting any medication regimen. Testosterone injections are typically administered subcutaneously (under the skin) or intramuscularly (into the muscle). Common subcutaneous sites include the abdomen, gluteus, thigh, and arm. Rotate injection sites with each injection to prevent tissue damage and irritation.

If your testosterone crystallizes or has crystals in the vial, submerge in warm water for several minutes or use a hair dryer until crystals disappear. Your medication is still safe and effective to continue utilizing.

Compounded Peptide Safety Information

Last Updated: November 2026

IMPORTANT NOTICE — PLEASE READ CAREFULLY

The information on this page applies to compounded preparations of the following peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon (also known as Epithalon), and Semax. These substances are not FDA-approved for any indication. Compounded drug products are not reviewed by the U.S. Food and Drug Administration (FDA) for safety, effectiveness, or quality before they are dispensed. Use of these peptides is at the sole discretion of the prescribing licensed healthcare provider and the individual patient.

FDA Status and Regulatory Position

None of the peptides listed above is an FDA-approved drug. They have not undergone the rigorous clinical trials required for FDA approval to demonstrate safety and efficacy for any medical condition.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that these six peptides be considered for inclusion on the 503A bulk drug substances list. That recommendation was non-binding. FDA scientific staff had recommended against inclusion based on limited or absent human safety and efficacy data.

On October 28, 2026, U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. issued an interim enforcement discretion policy (published in the Federal Register) stating that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound drug products containing these specific peptides while formal rulemaking continues, provided certain conditions are met. Those conditions include, among others:

  • Sourcing of bulk drug substance from an FDA-registered facility
  • Appropriate certificates of analysis, identity, purity, and impurity testing
  • Patient-specific prescriptions
  • Specified routes of administration for each peptide
  • Adverse event and quality-issue reporting
  • Single-ingredient compounding (blends/combinations are outside the policy)

This policy is not FDA approval. It is a temporary decision not to enforce existing restrictions under defined circumstances. The policy is non-binding, does not create any rights, and may be revised, limited, or withdrawn by HHS at any time, including if safety signals or product-quality issues arise. These peptides remain unapproved drugs under the Federal Food, Drug, and Cosmetic Act.

Marketed Uses (Not FDA-Approved Indications)

The following descriptions reflect common marketing claims and areas of research interest. They are not approved indications, and no claims of safety or effectiveness for these uses are made or implied:

  • BPC-157 — marketed for tissue repair and wound healing
  • TB-500 — marketed for soft-tissue recovery
  • KPV — marketed for anti-inflammatory effects and wound healing
  • MOTS-c — marketed for metabolic regulation and as an exercise mimetic
  • Epitalon — marketed for longevity support and sleep support
  • Semax — marketed for cognitive enhancement and neuroprotection

Any decision to use a compounded peptide must be made by a licensed healthcare provider after individualized evaluation. These products are intended only for use under the supervision of a qualified prescriber.

Warnings

  • These peptides have not been proven safe or effective in large, well-controlled human clinical trials for the marketed uses above.
  • Human safety and efficacy data are limited or absent for most of these substances. Long-term risks are unknown.
  • Potential theoretical risks discussed in the scientific literature include immunogenicity, pro-angiogenic effects (relevant to BPC-157 and TB-500), effects related to telomerase activity (Epitalon), and other uncharacterized systemic effects.
  • Injectable products carry risks of infection, injection-site reactions, and allergic responses.
  • Certain peptides (including BPC-157, TB-500, and MOTS-c) appear on anti-doping lists and are prohibited in competitive sports.
  • Safety has not been established in pregnancy, lactation, or in individuals with active or recent cancer, significant bleeding risk, or other serious medical conditions.
  • Product quality depends on the compounding pharmacy and the source of bulk substance. Even under the enforcement discretion policy, compounded products are not FDA-approved.

Potential Side Effects and Adverse Reactions

Because robust human clinical data are lacking, a complete side-effect profile is unknown. Reported or plausible reactions based on limited data, animal studies, and general peptide experience may include:

  • Injection-site reactions (pain, redness, swelling, irritation)
  • Allergic or hypersensitivity reactions (rash, itching, swelling; rare anaphylaxis)
  • Headache, fatigue, or flu-like symptoms
  • Gastrointestinal discomfort (particularly with oral forms)
  • Potential changes in blood glucose or other laboratory values (reported in some Semax data)
  • Unknown long-term effects, including possible immunogenicity or other systemic responses

Seek immediate medical attention for signs of a serious allergic reaction (difficulty breathing, swelling of the face/throat, severe rash) or any unexpected or severe symptoms.

Additional Legal Disclaimers — Compounded Peptides

  • This website does not sell peptides. Any compounded peptides are dispensed by a licensed pharmacy pursuant to a valid prescription from a licensed healthcare provider.
  • Information on this site is for educational purposes only and does not constitute medical advice, diagnosis, or treatment.
  • Individual results vary. No guarantees of outcomes are made or implied.
  • You are responsible for consulting your own licensed healthcare provider and for understanding the current regulatory status of any treatment you consider.
  • Laws and policies regarding compounding and unapproved drugs can change. Status information is current as of the date noted above and may be superseded by subsequent FDA or HHS actions.
  • The enforcement discretion policy does not authorize the sale of research-use-only (RUO) products for human use, nor does it cover products that fail to meet the stated conditions.

Limitation of Liability: To the fullest extent permitted by law, this website, its owners, operators, and affiliates disclaim all liability for any injury, loss, damage, or adverse outcome arising from the use of, or reliance on information about, compounded peptides. Use of any unapproved or compounded substance is undertaken at the patient's own risk after informed discussion with a qualified prescriber.

Consult a licensed healthcare provider before starting, stopping, or changing any treatment. This disclaimer is not a substitute for professional medical or legal advice.

If you are experiencing a medical emergency, call 911 or seek immediate medical attention. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.